Effect of Vyaghrihareetaki Avaleha and Granules on Tamaka Shwasa (Bronchial Asthma)

Pharmaceutical Standardization of Vyaghrihareetaki Avaleha and Granules and their effect on Tamaka Shwasa (Bronchial Asthma)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2011/12/002204

Enrollment

Registered

2011-12-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Tamaka shwasa Bronchial asthma

Interventions

Intervention1: Vyaghrihareetaki avaleha (Jaggery based): 10 gms twice daily for 4 weeks Control Intervention1: Vyaghrihareetaki avaleha (Sugar candy based): 10 gms twice daily for 4 weeks Control Inte

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients having signs and symptoms of Tamaka Shwasa as described in Ayurvedic classics. 2. Mild persistent cases of Asthma (as per WHO GINA Guideline) of duration more than 6 months. 3. Symptoms/exacerbation (Wheeze, cough and breathlessness) more than once a week but less than once a day in frequency

Exclusion criteria

Exclusion criteria: 1. Age more than 60 years and below 16 years. 2. Mild intermittent, Moderated persistent, severe persistent to severe Asthma. 3. Dyspnoea resulting from other diseases like left ventricular failure, COPD (Chronic Bronchitis, Emphysema), upper respiratory tract obstruction, bronchiectasis, cases of tuberculosis, interstitial lung disease/occupational lung disease, tropical pulmonary eosinophilia & allergic bronchopulmonary aspergillosis etc. 4. Patients having anaemia, pneumonia, tuberculosis, lung cancer, lung abscess and other such complicated conditions. 5. Patients having diabetes, hypertension, Chronic and Acute renal failure etc. conditions in which urination is markedly diminished or excessive were excluded. 6. HIV positive cases. 7. Pregnant/lactating mother. 8. Patients having classical symptoms of Maha, Urdha, Chinna and Kshudra Shwasa.

Design outcomes

Primary

Measure	Time frame
1.Changes in the cardinal symptoms of Tamaka shwasa. 2. Changes in ACQ and ACT score and PEFR.Timepoint: 0, 4 weeks	—

Secondary

Measure	Time frame
Respiratory rate and Breath holding timeTimepoint: 0, 4 weeks	—

Countries

India

Contacts

Public ContactRoshy Joseph C

Institute for Post Graduate Teaching and Research in Ayurveda

patgiri06@yahoo.co.in9426947438

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026